- US-listed companies
- RECURSION PHARMACEUTICALS, INC.
RECURSION PHARMACEUTICALS, INC.RXRX
Market cap
$1.6B
P/E ratio
| Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | |
| Operating revenue | 10 | 40 | 44 |
| Grant revenue | 0 | 0 | 1 |
| Revenue | 10 | 40 | 45 |
| Cost of revenue | - | 48 | 43 |
| Research and development | 135 | 156 | 241 |
| General and administrative | 58 | 82 | 111 |
| Total operating costs and expenses | - | 286 | 395 |
| Loss from operations | -183 | -246 | -350 |
| Other income (loss), net | -4 | 6 | 18 |
| Net loss | -186 | -239 | -328 |
| Loss before income tax benefit | - | - | -332 |
| Earnings Per Share, Basic | -1.49 | -1.36 | -1.58 |
| Earnings Per Share, Diluted | -1.49 | -1.36 | -1.58 |
| Income tax benefit | - | - | -4 |
| Net loss | -186 | -239 | -328 |
| Earnings Per Share, Basic | -1.49 | -1.36 | -1.58 |
| Earnings Per Share, Diluted | -1.49 | -1.36 | -1.58 |